H.C. Wainwright raised the firm’s price target on Tyra Biosciences (TYRA) to $23 from $19 and keeps a Buy rating on the shares. Given the positive competitive developments around pan-FGFR inhibitors entering the hypochondroplasia space, along with clinical success seen with FGFR inhibition in the achondroplasia indication from BridgeBio (BBIO), the firm adjusted its Tyra model to include potential upside associated with future development of TYRA-300 in HCH.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TYRA:
- Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
- Tyra Bioscience Announces New Purchase Agreement
- Tyra Bioscience Equity Sales Impact on Investor Decisions
- Tyra Bioscience Secures $200M for Clinical Drug Development
- Tyra Biosciences announces $200M private placement
